Pulsed Field Ablation: Disrupting the Cardiac Ablation Market in 2025

The global cardiac ablation devices market is witnessing a significant transformation thanks to the emergence of pulsed field ablation (PFA) technology. Since its introduction in 2021, PFA has been rapidly changing the way atrial fibrillation (AFib) is treated, providing an alternative to traditional methods like radiofrequency (RF) and cryoablation. This innovative technology is now driving growth in the pulsed field ablation market, which is expected to see rapid expansion over the next few years.

A New Era for Cardiac Ablation with Pulsed Field Ablation

PFA uses non-thermal electroporation to selectively target myocardial cells while sparing non-cardiac tissue, offering several advantages over traditional ablation techniques. This technology significantly reduces procedure times — by 30% to 50% — resulting in better cost-efficiency and improved patient outcomes. Clinical data supports the notion that PFA may eventually match or even exceed the effectiveness of RF and cryoablation. However, the real test will come over the long term, with durability data after three to five years being critical in comparing PFA with the established techniques.

Currently, the global pulsed field ablation market stands at $1 billion and is projected to grow at a compound annual growth rate (CAGR) of 32.2%, reaching $4.1 billion by 2029. This growth trajectory signals the rapid adoption of PFA technology, especially in the treatment of AFib. However, while the market for traditional RF and cryoablation devices continues to grow, PFA is expected to gradually take a larger share, potentially outpacing other ablation technologies by 2030.

Competitive Landscape: Major Players and Shifting Market Share

One of the most notable developments in the pulsed field ablation market is the rise of Boston Scientific, which has doubled its market share from 2023 to 2024. This growth follows its aggressive pursuit of PFA technology and its entry into the market with its own PFA system. As a result, Boston Scientific is now one of the top competitors in the space, challenging long-standing market leaders such as Medtronic and Johnson & Johnson’s Biosense Webster.

However, the path has not been easy for all players. Biosense Webster, for example, has faced delays and technical challenges with its PFA system, resulting in a contraction of its market share. Despite this, it is expected that with continued development and regulatory approvals, J&J and other major players will be able to carve out their space in the PFA market.


This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/pulsed-field-ablation-disrupting-the-cardiac-ablation-market-in-2025 

Comments

Post a Comment

Popular posts from this blog

The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...
Read more

Medtech in 2025: Key Insights from Q1 Earnings

  As we venture into Q2 of 2025, the medtech industry continues to navigate challenges while remaining on a positive growth trajectory. The early earnings reports from major medtech companies provide valuable insights into how the sector is performing and where it is heading. Despite the pressures of ongoing macroeconomic uncertainty, the first quarter of 2025 shows a sector that’s resilient, with many companies reporting strong growth across their key divisions. For more information visit here:  https://www.slideshare.net/slideshow/medtech-in-2025-key-insights-from-q1-earnings/279045324
Read more

Q1 2025 Medical Device Investment Roundup: A Record-Breaking Start to a Year of Reckoning

Big deals, even bigger questions. Jonathan Norris of HSBC Innovation Banking explains why 2025 is already one for the books. Venture investment across the medical device sector kicked off 2025 with a bang, posting $2.6 billion in first-quarter funding across 132 deals — the highest quarterly dollar mark in three years. According to  Jonathan Norris , Managing Director at  HSBC Innovation Banking , who writes comprehensive reports on the venture healthcare ecosystem, this surge marks a 20% rise in both capital and deal count compared to the 2024 average. “Not only did we have more dollars, but there were more deals, which is really good to see,” Norris says, in a recent interview with  The Lens . “I think the quick and easy takeaway is that more companies were getting funded in Q1, and a good percentage of the bigger deals in the quarter were PMA pivotal trial rounds. It looks like positive momentum for the sector to see a big quarter. That’s our 35,000-foot view.” But ben...
Read more